The company plans to kick off the G6 commercial launch later this year.
Dexcom’s G6 device includes a transmitter, a sensor with an auto-applicator and a touchscreen receiver. The product does not require fingersticks and continuous glucose readings can be sent to any compatible, Bluetooth-linked smart device, according to the company.
“The Dexcom G6 represents another step forward in diabetes management,” Paul Flynn, VP of Dexcom Canada, said in prepared remarks. “This next generation product continues the performance, features, and accuracy that the diabetes community has come to expect from Dexcom CGM. We’re proud and excited to be able to bring it to Canadians this year, once we’re in a position to reliably meet demand.”
Also last week, Dexcom topped expectations on Wall Street with its fourth-quarter and full-year financial results.
In the same SEC filing, the company revealed that it plans to expand its customer support services and that this would “result in a reduction in certain areas of the company’s domestic workforce” by the end of 2019.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.